• (S)-(+)-Methoprene Workflows for JH Research

  2026-09-03

  Build stage-resolved assays for juvenile hormone signaling, insect metamorphosis inhibition, and reproductive regulation with a defined juvenile hormone analog. This guide connects Met-receptor perturbation with miRNA–mRNA analysis while providing practical dosing, sampling, and troubleshooting strategies.

• X-press Tag Peptide for Mechanistic Assays

  2026-09-03

  Discover how the X-press Tag Peptide supports reproducible purification, orthogonal detection, and cleavage-aware analysis of recombinant proteins. This article translates new RHEB neddylation findings into practical assay design decisions.

• Cisapride (R 51619) in Cardiac Research

  2026-09-02

  Cisapride, also known as R 51619, is a research compound that combines nonselective 5-HT4 receptor agonism with hERG channel inhibition. Its dual pharmacology supports mechanistic studies spanning the 5-HT4 receptor signaling pathway, cardiac electrophysiology research, and cardiac arrhythmia research, but it does not replace direct electrophysiology or clinical assessment.

• Polymyxin B Sulfate: Research Workflows

  2026-09-02

  Polymyxin B sulfate is a membrane-active tool for Gram-negative infection studies, LPS perturbation experiments, and carefully controlled immune assays. This guide connects practical handling and assay design with microbiome-focused findings from an allergic rhinitis rat study without overstating what the reference research demonstrated.

• One-step TUNEL Cy5 Apoptosis Detection Kit Guide

  2026-09-01

  Build a quantitative apoptosis workflow for bone-tissue sections, adherent cells, suspension cells, and flow cytometry with far-red Cy5 detection. This guide connects DNA fragmentation readouts to the PTX3–TLR4/NF-κB–FGF21 findings in glucocorticoid-induced osteonecrosis while emphasizing controls, assay boundaries, and troubleshooting.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-01

  The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for cell proliferation studies, cell lineage tracing, and flow cytometry or microscopy workflows. It is intended for persistent covalent marking rather than reversible or short-term staining, and the supplied dossier does not define a universal labeling concentration or incubation schedule.

• Urine Nanosensor for Early Atherosclerosis

  2026-08-31

  Wu et al. developed an enzymatic cleavage-triggered carbon quantum dot nanosensor that converts atherosclerosis-associated proteolytic activity into a fluorescent urine signal. In mouse experiments, the platform distinguished early atherosclerotic animals from healthy controls and showed no notable toxicity, supporting its potential as a minimally invasive preclinical screening strategy.

• Annexin V-Cy5/DAPI Apoptosis Kit Guide

  2026-08-30

  Turn phosphatidylserine exposure and membrane integrity into a rapid, two-parameter cell-death readout. This workflow shows how to apply the Annexin V-Cy5/DAPI Apoptosis Kit to drug-response studies, including P2RX1-driven mitochondrial apoptosis in Ph+ ALL, while avoiding common staining and gating errors.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-29

  A 2025 mouse study identifies thymoquinone as a protective intervention in doxorubicin-induced cardiac injury and links its effects to Nrf2/HO-1 activation, oxidative-stress control, and reduced ferroptosis-associated damage. The work integrates cardiac function, biochemical, protein-expression, immunohistochemical, and ultrastructural endpoints, while leaving pathway causality and clinical translation for further study.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-29

  The reference study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy that suppresses growth, migration, stem-like behavior, and tumorigenesis across molecular subtypes of breast cancer. Its mechanistic contribution is the linkage of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, connecting oncogenic signaling with chromatin regulation.

• Methoxy-X04 for Amyloid Beta Imaging

  2026-08-28

  Methoxy-X04 is a brain-permeable fluorescent amyloid beta probe for connecting plaque burden, vascular amyloid, and aggregate-associated pathology with treatment biology. This workflow applies the probe to exercise and extracellular-vesicle studies, with practical controls for formulation, timing, image analysis, and interpretation.

• IR-1061 Workflow for NIR Deep-Tissue Imaging

  2026-08-28

  IR-1061 is a near infrared fluorescent dye suited to OTN-NIR workflows where deep-tissue contrast and low background are priorities. This guide translates dye handling, nanoparticle loading, assay design, and troubleshooting into a practical workflow for biomedical imaging research.

• Paroxetine and Thiothixene Pharmacokinetics

  2026-08-27

  The reference study used a controlled human crossover design to test whether paroxetine, a potent CYP2D6 inhibitor, alters thiothixene disposition. Short-term paroxetine pretreatment did not significantly change thiothixene pharmacokinetic parameters, suggesting that CYP2D6 is unlikely to account for a major proportion of clearance while leaving longer-term or alternative metabolic pathways unresolved.

• Prochlorperazine: Bench Workflows and Safety Insights

  2026-08-27

  Prochlorperazine connects dopamine D2 receptor pharmacology with practical melanoma and endocytosis assays. This guide translates a clinically important stroke-mimic case into reproducible cell-based workflows, concentration screens, controls, and troubleshooting strategies.

• NAT1–ENO1–Lactate Axis in Colorectal Cancer

  2026-08-26

  A 2026 MedComm study identifies a metabolic–immune pathway in colorectal cancer in which NAT1 restrains ENO1 activity and lactate production, while NAT1 loss promotes TRAF6-dependent PD-L1 stabilization. The findings connect tumor glycolysis with immune checkpoint regulation and suggest that NAT1 status and lactate-associated mechanisms may help explain responses to PD-1 or PD-L1 blockade.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page